Jaguar Health presents crofelemer SBS study data
- Jaguar Health announced acceptance of an abstract covering preliminary adult short bowel syndrome study results at ACG 2026.
- The ongoing study evaluates crofelemer in adults with short bowel syndrome and intestinal failure.
- Napo Pharmaceuticals is also conducting a Phase 2 trial in adults with Type 1 short bowel syndrome, with results expected in 2027.
Jaguar Health (NASDAQ:JAGX) announced that an abstract covering preliminary results from an adult short bowel syndrome study has been accepted for presentation at the American College of Gastroenterology (ACG) 2026 meeting.
The abstract focuses on an ongoing open-label study evaluating crofelemer in adults with short bowel syndrome and intestinal failure (SBS-IF).
Jaguar Health said the ACG 2026 presentation will take place during the meeting scheduled for October 9–14, 2026, while Napo Pharmaceuticals continues a controlled Phase 2 trial of crofelemer in adults with Type 1 short bowel syndrome.
The company said results from the Phase 2 trial are expected in the early second half of 2027, while previously presented pediatric investigations reported reduced weekly parenteral support requirements after more than one year of oral liquid crofelemer treatment.
Jaguar said it plans to submit a drug application for microvillus inclusion disease in mid-2027.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
